Nucleolin aptamer conjugated MSNPs-PLR-PEG multifunctional nanoconstructs for targeted co-delivery of anticancer drug and siRNA to counter drug resistance in TNBC
Graphical abstract
Introduction
Triple-negative breast cancer (TNBCs), arguably, is the most aggressive form of breast cancer and is characterized by lack of hormone receptors (ERs and PRs) and excessive expression of HER2 [1]. The majority of TNBC patients demonstrate an inadequate response to treatment strategies. Only ∼35–40 % of patients suffering from TNBCs show a complete pathological response (pCR) with similar survival rates. Approximately 15–20 % of the young female (<40 years) population diagnosed with breast cancer are found to be suffering from TNBCs [2]. Patients suffering from TNBCs are expected to demonstrate a first 5-year survival rate of 70 %, i.e., 10 % lower than other breast cancer subtypes [3]. Currently, a significant hurdle in developing an appropriate treatment strategy for TNBCs is the heterogeneity of TNBCs and their resistance to various treatment strategies [4], [5], [6]. The primary treatment strategy for TNBCs involves a chemotherapeutic approach comprising the regulated use of anthracyclines, taxanes, or platinum compounds for disrupting cancer cells. Since most TNBC patients receiving chemotherapy do not reach pCR, a discussion regarding whether chemotherapy choices need to be distinct for TNBCs is ongoing [7]. Various treatment strategies presently used clinically for TNBCs are not highly effective due to the lack of targets known to be frequently involved in driving oncogenic transformation [4]. Further, other therapies, like hormone therapy, immunotherapy, radiation therapy, surgery, etc., are conventionally employed for the treatment. However, the usage of these therapies is limited by significant side effects, reduced efficacy, and resistance to anticancer drugs. The development of resistance to chemotherapy could be ascribed to the genetically highly diverse population of tumor cells in TNBCs, which can overcome treatment by enhanced expression of anti-apoptotic genes or genes involved in drug-metabolizing pathways [8], [9]. In such a scenario, siRNAs hold tremendous potential as targeted therapeutics. The ability of small interfering RNAs (siRNA) to silence desired genes selectively has generated massive awareness of their use as therapeutic agents. These siRNAs can be delivered to cancer cells using nanocarriers [10]. The inclusion of siRNA in nanocarrier systems may be through physical entrapment, electrostatic interaction, or chemical conjugation [11]. However, the use of either siRNA or drug is insufficient to combat the emerging threat of drug resistance. One approach to overcome the issue is to co-deliver the drug and siRNA, where siRNA can modulate the expression level of the molecules responsible for resistance, thus enhancing the drug's chemotherapeutic effect. However, due to various limitations, delivering drug and siRNA together is a formidable task. Nanotechnology is at the forefront in offering multiple options to co-deliver different bioactive molecules. One such nanocarrier, MSNP, has shown great potential for the co-delivery of cargo.
MSNPs have emerged as promising drug carriers because of tunable pore sizes and high pore volume [12], [13], [14]. The possibility of diverse surface functionalization allows MSNPs to interact with a range of agents like polymers, dendrimers, bio-macromolecules, nanoparticles, and even therapeutic drugs. Considering these facts, few researchers have shown effective co-delivery of drugs and other biomacromolecules (e.g., siRNAs) using MSNPs. These reports have primarily utilized passive targeting of the nanocarrier to the target site. Passive targeting (based on the EPR effect) forms the basis of various cancer treatment strategies, but it has a few drawbacks [15], [16], [17]. Variation in the diffusion efficiency of drug molecules makes it increasingly harder to target all the cells within the tumor. Furthermore, lack of specificity in passive targeting leads to difficulty in process control, ultimately resulting in drug resistance. On the other hand, active targeting utilizes molecules on the nanocarrier, which can bind specifically to a receptor on cancer cells. This approach provides a greater degree of control than passive targeting wherein, post extravasation, the nanocarriers bind to cancer cells through specific interaction. Such binding specificity could be achieved by modifying nanocarriers with cancer-targeting antigens through various conjugation chemistries [18], [19]. These nanocarriers utilize receptor-ligand interactions for recognizing tumor cells, and the bound nanocarriers are effectively internalized by tumor cells, wherein the therapeutic molecules are released. A pre-requisite for such an approach is the overexpression of the receptors on cancer cells allowing targeting of these cells [12], [20].
Nucleolin is one such antigen localized on the surface of tumor cells on nucleolus dissolution. The dissolution of the nucleolus is one of the hallmarks of cancers, which also results in the dysregulation of nucleolar activities [21]. The disintegration of the nucleolus results in the release of the protein machinery [including nucleoplasmin and nucleolin (NCL)] in the cytoplasm [22]. The released NCL localizes to the membrane of the cancer cells, and thus, cancer cells pose an enhanced presence of NCL on their surface. The enhanced representation of NCL on cancer cell membranes makes them promising molecules for targeting cancer cells. To achieve nucleolin targeting, an aptamer, AS1411, has been developed against it. It is a 26-base, G-rich DNA oligonucleotide that functions as the NCL-binding aptamer [23]. AS1411 can be used to develop a platform that can effectively target different types of cancers, owing to the presence of NCL on the surface of various cancer cells. Hence, AS1411 holds tremendous potential to target nanocarriers to a wide range of cancer cells.
The present study aimed to develop an MSNPs-based nanocarrier for targeted co-delivery of drug and siRNA to drug-resistant TNBCs. To achieve this, MSNPs were sequentially modified with poly-L-arginine (PLR) and PEG. To develop a targeted nanocarrier, AS1411 aptamer has been conjugated to MSNPs-PLR-PEG in the present study. In parallel, TNBC cells (MDA MB-231) were made resistant to DOX. The developed nanocarrier protected siRNA against serum-nuclease for up to 24 h and was found to be biocompatible. The co-delivery of DOX and siRNA against BCL-xL and BCL-2 showed >10- and 40-fold reduction in IC50 of DOX, respectively. These results were further validated on the cells grown on 3D scaffolds. Thus, the present work highlights the potential of a developed nanocarrier against highly aggressive TNBC.
Section snippets
Materials
Tetraethyl orthosilicate (TEOS; Merck, USA), Cetyl trimethyl ammonium chloride (CTAC; Merck, USA), Triethanolamine (TEA; Merck, USA), Methanol (Spectrochem, India), Hydrochloric acid (Qualigens, India), Triscarboxyethylphosphine (TCEP; Merck, USA), Poly-L-arginine (Merck, USA), AS1411 Aptamer (Invitrogen, USA), anti-BCL-2 siRNA (Invitrogen, USA), anti-BCL-xL siRNA (Invitrogen, USA), Scrambled/negative control siRNA (NC; Invitrogen, USA), Maleimide-PEG-NHS (2000 Da; Merck, USA), NHS-PEG-OCH3
Characterization of MSNPs
The size and surface charges of the MSNPs, as determined by DLS, were found to be 65.4 ± 10.6 nm and −10.6 mV, respectively (Fig. 1 A and B). The net negative surface charge could be attributed to the presence of silanol groups (SiOH) on the surface of the MSNPs. The SEM micrograph (Fig. 1 C) showed that the nanoparticles were nearly spherical with a size close to 50 nm. The significant difference in the size observed in DLS and SEM is due to hydrodynamic radii measured in the case of DLS. The
Conclusion
The primary aim of the work, i.e., targeted co-delivery of DOX and siRNA (BCL-2/BCL-xL) using MSNPs-based multifunctional nanocarrier for the treatment of drug-resistant cancer cells, was achieved and successfully demonstrated in the in vitro 3D cell culture. The targeted nanocarrier (MSNP-PLR-PEG-AS1411) was significantly effective in the co-delivery of DOX and siRNA compared to the non-targeted nanocarrier. These results suggest potentially reduced requirement of DOX dosage as well as
CRediT authorship contribution statement
Pramod Kumar: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Software; Validation; Visualization; Roles/Writing - original draft;
Rajesh Salve: Data curation; Formal analysis; Investigation; Methodology; Roles/Writing - original draft;
K. M. Paknikar: Conceptualization; Resources; Supervision; Validation; Writing - review & editing.
Virendra Gajbhiye: Conceptualization; Funding acquisition; Project administration; Supervision; Validation; Writing - review & editing.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References (71)
- et al.
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks
Cell
(2012) - et al.
Role of breast cancer resistance protein (bcrp/abcg2) in cancer drug resistance
Biochem. Pharmacol.
(2012) - et al.
siRNA-nanoparticle conjugate in gene silencing: a future cure to deadly diseases?
Mater. Sci. Eng. C
(2017) - et al.
Rerouting engineered metal-dependent shapes of mesoporous silica nanocontainers to biodegradable janus-type (sphero-ellipsoid) nanoreactors for chemodynamic therapy
Chem. Eng. J.
(2019) - et al.
Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
Mater. Sci. Eng. C
(2019) - et al.
Ultrasmall platinum nanoparticles enable deep tumor penetration and synergistic therapeutic abilities through free radical species-assisted catalysis to combat cancer multidrug resistance
Chem. Eng. J.
(2020) - et al.
Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: a review
Mater. Sci. Eng. C
(2020) Polymeric nanoparticles for targeted drug delivery system for cancer therapy
Mater. Sci. Eng. C
(2016)- et al.
Smart triblock dendritic unimolecular micelles as pioneering nanomaterials: advancement pertaining to architecture and biomedical applications
J. Control. Release
(2019) - et al.
The nucleolus: an emerging target for cancer therapy
Trends Mol. Med.
(2013)
Broad targeting of resistance to apoptosis in cancer
Semin. Cancer Biol.
In vitro siRNA delivery via diethylenetriamine- and tetraethylenepentamine-modified carboxyl group-terminated Poly(amido)amine generation 4.5 dendrimers
Mater. Sci. Eng. C
Polyester based nanovehicles for siRNA delivery
Mater. Sci. Eng. C
An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles
Biomaterials
In vivo veritas: bcl-2 and bcl-X(L)mediate tumor cell resistance to chemotherapy
Drug Resist. Updat.
A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V
J. Immunol. Methods
Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H(2)O(2)- and p53-dependent pathways
J. Biol. Chem.
Dedifferentiated chondrocytes re-express the differentiated collagen phenotype when cultured in agarose gels
Cell
Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation
Semin. Cancer Biol.
Multicellular spheroids in ovarian cancer metastases: biology and pathology
Gynecol. Oncol.
From 3D cell culture to organs-on-chips
Trends Cell Biol.
Modeling tissue morphogenesis and cancer in 3D
Cell
Triple-negative breast cancer: disease entity or title of convenience?
Nat. Rev. Clin. Oncol.
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry
Cancer
Update on triple-negative breast cancer: prognosis and management strategies
Int. J. Women's Health
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
J. Clin. Invest.
The omics of triple-negative breast cancers
Clin. Chem.
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer
Clin. Cancer Res.
The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis
Breast Cancer Res. Treat.
Triptorelin tethered multifunctional PAMAM-histidine-PEG nanoconstructs enable efficient targeting and gene silencing in LHRH overexpressing breast and prostate cancer cells
ACS Appl. Mater. Interfaces
Mesoporous silica nanoparticles as cutting-edge theranostics: advancement from merely a carrier to tailor-made smart delivery platform
J Control Release
Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications
J. Nanobiotechnol.
Nanoarchitectured structure and surface biofunctionality of mesoporous silica nanoparticles
Adv. Mater.
Nucleolar size indicates the rapidity of cell proliferation in cancer tissues
J. Pathol.
Aptamer-based targeted delivery of a G-quadruplexligand in cervical cancer cells
Sci. Rep.
Cited by (10)
Nanocarriers for delivering nucleic acids and chemotherapeutic agents as combinational approach: Challenges, clinical progress, and unmet needs
2024, Journal of Drug Delivery Science and TechnologyAptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat
2023, Biochimica et Biophysica Acta - Molecular Basis of DiseaseApplication of aptamer-drug delivery system in the therapy of breast cancer
2023, Biomedicine and PharmacotherapyTargeting triple negative breast cancer stem cells using nanocarriers
2024, Discover Nano